vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and QUALYS, INC. (QLYS). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $175.3M, roughly 1.6× QUALYS, INC.). QUALYS, INC. runs the higher net margin — 30.3% vs -45.7%, a 76.0% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 10.1%). QUALYS, INC. produced more free cash flow last quarter ($74.9M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 9.6%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
Qualys, Inc. is an American technology firm based in Foster City, California, specializing in cloud security, compliance and related services.
GH vs QLYS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $175.3M |
| Net Profit | $-128.5M | $53.1M |
| Gross Margin | 64.6% | 83.4% |
| Operating Margin | -43.0% | 33.6% |
| Net Margin | -45.7% | 30.3% |
| Revenue YoY | 39.4% | 10.1% |
| Net Profit YoY | -15.8% | 20.9% |
| EPS (diluted) | $-1.01 | $1.47 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | $175.3M | ||
| Q3 25 | $265.2M | $169.9M | ||
| Q2 25 | $232.1M | $164.1M | ||
| Q1 25 | $203.5M | $159.9M | ||
| Q4 24 | $201.8M | $159.2M | ||
| Q3 24 | $191.5M | $153.9M | ||
| Q2 24 | $177.2M | $148.7M | ||
| Q1 24 | $168.5M | $145.8M |
| Q4 25 | $-128.5M | $53.1M | ||
| Q3 25 | $-92.7M | $50.3M | ||
| Q2 25 | $-99.9M | $47.3M | ||
| Q1 25 | $-95.2M | $47.5M | ||
| Q4 24 | $-111.0M | $44.0M | ||
| Q3 24 | $-107.8M | $46.2M | ||
| Q2 24 | $-102.6M | $43.8M | ||
| Q1 24 | $-115.0M | $39.7M |
| Q4 25 | 64.6% | 83.4% | ||
| Q3 25 | 64.7% | 83.6% | ||
| Q2 25 | 65.0% | 82.4% | ||
| Q1 25 | 63.3% | 81.9% | ||
| Q4 24 | 61.6% | 81.8% | ||
| Q3 24 | 61.1% | 81.3% | ||
| Q2 24 | 59.1% | 82.2% | ||
| Q1 24 | 61.2% | 81.3% |
| Q4 25 | -43.0% | 33.6% | ||
| Q3 25 | -37.3% | 35.3% | ||
| Q2 25 | -45.9% | 31.3% | ||
| Q1 25 | -54.6% | 32.4% | ||
| Q4 24 | -62.4% | 31.0% | ||
| Q3 24 | -61.3% | 29.2% | ||
| Q2 24 | -56.8% | 32.3% | ||
| Q1 24 | -59.2% | 30.7% |
| Q4 25 | -45.7% | 30.3% | ||
| Q3 25 | -35.0% | 29.6% | ||
| Q2 25 | -43.0% | 28.8% | ||
| Q1 25 | -46.8% | 29.7% | ||
| Q4 24 | -55.0% | 27.6% | ||
| Q3 24 | -56.3% | 30.0% | ||
| Q2 24 | -57.9% | 29.4% | ||
| Q1 24 | -68.2% | 27.2% |
| Q4 25 | $-1.01 | $1.47 | ||
| Q3 25 | $-0.74 | $1.39 | ||
| Q2 25 | $-0.80 | $1.29 | ||
| Q1 25 | $-0.77 | $1.29 | ||
| Q4 24 | $-0.90 | $1.19 | ||
| Q3 24 | $-0.88 | $1.24 | ||
| Q2 24 | $-0.84 | $1.17 | ||
| Q1 24 | $-0.94 | $1.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $250.3M |
| Total DebtLower is stronger | $1.5B | — |
| Stockholders' EquityBook value | $-99.3M | $561.2M |
| Total Assets | $2.0B | $1.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | $250.3M | ||
| Q3 25 | $580.0M | $225.3M | ||
| Q2 25 | $629.1M | $194.0M | ||
| Q1 25 | $698.6M | $290.7M | ||
| Q4 24 | $525.5M | $232.2M | ||
| Q3 24 | $585.0M | $235.4M | ||
| Q2 24 | $933.7M | $281.2M | ||
| Q1 24 | $1.0B | $273.8M |
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-99.3M | $561.2M | ||
| Q3 25 | $-354.5M | $529.4M | ||
| Q2 25 | $-305.5M | $508.2M | ||
| Q1 25 | $-250.8M | $498.0M | ||
| Q4 24 | $-139.6M | $477.1M | ||
| Q3 24 | $-60.1M | $449.6M | ||
| Q2 24 | $-1.6M | $427.8M | ||
| Q1 24 | $68.3M | $404.2M |
| Q4 25 | $2.0B | $1.1B | ||
| Q3 25 | $1.3B | $1.0B | ||
| Q2 25 | $1.3B | $999.5M | ||
| Q1 25 | $1.3B | $996.5M | ||
| Q4 24 | $1.5B | $973.5M | ||
| Q3 24 | $1.5B | $908.3M | ||
| Q2 24 | $1.6B | $876.6M | ||
| Q1 24 | $1.7B | $861.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $75.7M |
| Free Cash FlowOCF − Capex | $-54.2M | $74.9M |
| FCF MarginFCF / Revenue | -19.3% | 42.8% |
| Capex IntensityCapex / Revenue | 9.9% | 0.4% |
| Cash ConversionOCF / Net Profit | — | 1.42× |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $304.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | $75.7M | ||
| Q3 25 | $-35.4M | $90.4M | ||
| Q2 25 | $-60.3M | $33.8M | ||
| Q1 25 | $-62.7M | $109.6M | ||
| Q4 24 | $-64.5M | $47.7M | ||
| Q3 24 | $-51.1M | $61.0M | ||
| Q2 24 | $-94.0M | $49.8M | ||
| Q1 24 | $-30.3M | $85.5M |
| Q4 25 | $-54.2M | $74.9M | ||
| Q3 25 | $-45.8M | $89.5M | ||
| Q2 25 | $-65.9M | $32.4M | ||
| Q1 25 | $-67.1M | $107.5M | ||
| Q4 24 | $-83.4M | $41.9M | ||
| Q3 24 | $-55.3M | $57.6M | ||
| Q2 24 | $-99.1M | $48.8M | ||
| Q1 24 | $-37.2M | $83.5M |
| Q4 25 | -19.3% | 42.8% | ||
| Q3 25 | -17.3% | 52.7% | ||
| Q2 25 | -28.4% | 19.8% | ||
| Q1 25 | -33.0% | 67.3% | ||
| Q4 24 | -41.3% | 26.3% | ||
| Q3 24 | -28.9% | 37.4% | ||
| Q2 24 | -55.9% | 32.8% | ||
| Q1 24 | -22.1% | 57.2% |
| Q4 25 | 9.9% | 0.4% | ||
| Q3 25 | 3.9% | 0.5% | ||
| Q2 25 | 2.4% | 0.8% | ||
| Q1 25 | 2.2% | 1.3% | ||
| Q4 24 | 9.4% | 3.7% | ||
| Q3 24 | 2.2% | 2.2% | ||
| Q2 24 | 2.9% | 0.7% | ||
| Q1 24 | 4.1% | 1.4% |
| Q4 25 | — | 1.42× | ||
| Q3 25 | — | 1.80× | ||
| Q2 25 | — | 0.71× | ||
| Q1 25 | — | 2.31× | ||
| Q4 24 | — | 1.09× | ||
| Q3 24 | — | 1.32× | ||
| Q2 24 | — | 1.14× | ||
| Q1 24 | — | 2.15× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
QLYS
| Sales Channel Through Intermediary | $88.6M | 51% |
| Sales Channel Directly To Consumer | $86.7M | 49% |
